<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Mol. Med</journal-id><journal-id journal-id-type="publisher-id">IJMM</journal-id><journal-title-group><journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1107-3756</issn><issn pub-type="epub">1791-244X</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7307834</article-id><article-id pub-id-type="doi">10.3892/ijmm.2020.4640</article-id><article-id pub-id-type="publisher-id">ijmm-46-02-0463</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>COVID-19: Post-lockdown guidelines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kostoff</surname><given-names>Ronald N.</given-names></name><xref ref-type="aff" rid="af1-ijmm-46-02-0463">1</xref><xref ref-type="corresp" rid="c1-ijmm-46-02-0463"/></contrib><contrib contrib-type="author"><name><surname>Briggs</surname><given-names>Michael B.</given-names></name><xref ref-type="aff" rid="af2-ijmm-46-02-0463">2</xref></contrib><contrib contrib-type="author"><name><surname>Porter</surname><given-names>Alan L.</given-names></name><xref ref-type="aff" rid="af3-ijmm-46-02-0463">3</xref></contrib><contrib contrib-type="author"><name><surname>Aschner</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af4-ijmm-46-02-0463">4</xref></contrib><contrib contrib-type="author"><name><surname>Spandidos</surname><given-names>Demetrios A.</given-names></name><xref ref-type="aff" rid="af5-ijmm-46-02-0463">5</xref></contrib><contrib contrib-type="author"><name><surname>Tsatsakis</surname><given-names>Aristidis</given-names></name><xref ref-type="aff" rid="af6-ijmm-46-02-0463">6</xref><xref ref-type="corresp" rid="c2-ijmm-46-02-0463"/></contrib></contrib-group><aff id="af1-ijmm-46-02-0463">
<label>1</label>School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155</aff><aff id="af2-ijmm-46-02-0463">
<label>2</label>Independent Consultant, Roscommon, MI 48653</aff><aff id="af3-ijmm-46-02-0463">
<label>3</label>School of Public Policy, Georgia Institute of Technology, Atlanta, GA 30332</aff><aff id="af4-ijmm-46-02-0463">
<label>4</label>Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA</aff><aff id="af5-ijmm-46-02-0463">
<label>5</label>Laboratory of Clinical Virology</aff><aff id="af6-ijmm-46-02-0463">
<label>6</label>Laboratory of Toxicology, Medical School, University of Crete, 70013 Heraklion, Greece</aff><author-notes><corresp id="c1-ijmm-46-02-0463">Correspondence to: Dr Ronald N. Kostoff, School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA E-mail: <email>rkostoff@gmail.com</email></corresp><corresp id="c2-ijmm-46-02-0463">Professor Aristidis Tsatsakis, Laboratory of Toxicology, Medical School, University of Crete, 70013 Heraklion, Greece E-mail: <email>tsatsaka@uoc.gr</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>46</volume><issue>2</issue><fpage>463</fpage><lpage>466</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Kostoff et al.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><kwd-group><kwd>coronavirus</kwd><kwd>COVID-19</kwd><kwd>ARS-CoV-2</kwd><kwd>severe acute respiratory syndrome</kwd><kwd>SARS-CoV</kwd><kwd>Middle East respiratory syndrome</kwd><kwd>MERS-CoV</kwd><kwd>pandemic</kwd><kwd>lockdown</kwd><kwd>immune system</kwd></kwd-group></article-meta></front><body><sec sec-type="other"><title>COVID-19</title><p>Since March, 2020, in response to the COVID-19 pandemic, many countries have been on lockdown (at different levels of severity), restricting many activities and businesses that involve gatherings of large numbers of people in close proximity. Currently (early June, 2020), countries across the globe are in different stages of easing lockdown restrictions. Public policies for behaviors and actions during this transition period vary widely across countries and within country jurisdictions. The present editorial will address potential policies that could minimize resurgence of the present pandemic (the 'second-wave') and reduce the likelihood and severity of similar future pandemics.</p></sec><sec sec-type="other"><title>Prior coronavirus pandemics</title><p>Over the past two decades, there have been at least three major coronavirus-based infectious disease outbreaks/epidemics/pandemics: severe acute respiratory syndrome (SARS), 2002-2003; Middle East respiratory syndrome (MERS), starting in 2012; COVID-19, starting in December 2019. There are a number of biomarker, symptom, and other similarities among these three infectious diseases (and influenza as well). For these infectious diseases, the members of the demographic affected most severely tend to be the elderly, with multiple comorbidities, and others with weakened immune systems (<xref rid="b1-ijmm-46-02-0463" ref-type="bibr">1</xref>-<xref rid="b12-ijmm-46-02-0463" ref-type="bibr">12</xref>). While there is some decline in the immune system with age, comorbidity is a stronger predictor of impaired immunity than chronological age in older adults (<xref rid="b13-ijmm-46-02-0463" ref-type="bibr">13</xref>,<xref rid="b14-ijmm-46-02-0463" ref-type="bibr">14</xref>).</p><p>The main measures being taken to control the spread of SARS-CoV-2 (the virus associated with COVID-19) are conceptually those that were taken to control the spread of SARS-CoV in 2002-2003: good hygiene, facemasks, and quarantine. The difference is the larger scale of these measures for SARS-CoV-2.</p></sec><sec sec-type="other"><title>Approaches to augment or strengthen immune system</title><p>A strong immune system responds appropriately to the challenge; a weak immune system may over-respond or under-respond. A weakened immune system appears to be the main determinant of serious/fatal reaction to viral infection (for COVID-19, SARS, and influenza alike). There are four major approaches being employed or considered presently to augment or strengthen the immune system, in order to reduce adverse effects of viral exposure. The three approaches that are mainly focused on augmenting the immune system are based on the concept that pandemics can be controlled/prevented while maintaining the immune-weakening lifestyles followed by much of the global population. The fourth approach is based on identifying and introducing measures aimed at strengthening the immune system intrinsically in order to minimize future pandemics.</p><p><italic>Restriction of exposure to virus</italic>. First are measures to restrict exposure to the virus. This includes social distancing, quarantine, frequent hand-washing, wearing facemasks, restricting large gatherings, etc. These measures will reduce the viral load people will experience, and therefore reduce the levels of viruses to be neutralized by the immune system. However, relative to 'clean rooms' for i) planetary NASA mission preparation or ii) allogeneic haematopoietic stem cell transplantation patient recuperation, these measures will still allow viral transmission and infection to occur.</p><p>These measures do not strengthen the immune system, and may in fact weaken the immune systems of healthy people by restricting those continual immune challenges that strengthen the healthy immune system. Continuing these restrictive measures during the post-lockdown transition period may be useful for the most vulnerable demographic described above, but may be overly restrictive for the vast majority of the population. There is no unanimity within the medical community on whether or not it is counter-productive to require severe restrictions on the vast majority of the total population when only required by a very small minority of the total population.</p><p><italic>Reactive/tactical treatments</italic>. Second are reactive/tactical measures to restrict the viral load on the immune system, such that the immune system does not become overwhelmed. Much of the effort to help especially the most vulnerable demographic at this time has been searching for, and experimenting with, treatments that were/are used to combat other mainly viral diseases (<xref rid="b15-ijmm-46-02-0463" ref-type="bibr">15</xref>). As of 1 June, 2020, these treatments include, but are not limited to:</p><p>Actemra/Tocilizumab; Avigan/Favipiravir; Azithromycin; Baricitinib/Olumiant; Bevacizumab/Avastin; Calquence/Acalabrutinib; Chloroquine; Colcrys/Colchicine; Convalescent Plasma; EIDD-2801; Fingolimod/Gilenya; Galidesivir; Hydroxychloroquine; Ilaris/Canakinumab; Ivermectin; Jakafi/Ruxolitinib; Kaletra/Lopinavir/Ritonavir; Kevzara/Sarilumab; Kineret/Anakinra; Leronlimab; Mavrilimumab; Methylprednisolone; Olumiant/Baricitinib; Otezla/Apremilast; Remdesivir; Tamiflu/Oseltamivir; Umifenovir/Arbidol; Xeljanz/Tofacitinib (<ext-link ext-link-type="uri" xlink:href="https://milkeninstitute.org/covid-19-tracker">https://milkeninstitute.org/covid-19-tracker</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://www.drugs.com/condition/covid-19.html">https://www.drugs.com/condition/covid-19.html</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://www.goodrx.com/blog/coronavirus-treatments-on-the-way/">https://www.goodrx.com/blog/coronavirus-treatments-on-the-way/</ext-link>). The treatment trials have met with mixed results, and, in any case, do little, if anything, to strengthen the weakened immune systems of the most vulnerable. After such tactical treatments for one viral infection, people with weakened immune systems will again be vulnerable to serious infectious consequences from exposure to the next harmful virus they encounter, unless they take active measures to strengthen their immune systems. Local treatments (aerosol, inhalers, nebulizers) may offer some benefit of achieving ther-apeutic concentrations in affected tissues with lower adverse effects (<xref rid="b16-ijmm-46-02-0463" ref-type="bibr">16</xref>).</p><p><italic>Vaccines</italic>. Third are the vaccines. Their purpose is to prevent, or at least attenuate, the infection. They do not strengthen a weakened immune system intrinsically, but, if effective, act as a crutch to the immune system's capability to neutralize the virus.</p><p>A recent study examined myriad COVID-19 vaccines under development (<xref rid="b17-ijmm-46-02-0463" ref-type="bibr">17</xref>). As stated in this reference: 'Normally, the period of development of a vaccine is 12-15 years'. Against this backdrop, SARS-CoV-2 vaccines are being targeted for accelerated development by an order of magnitude. Each of the accelerated steps listed in this reference (<xref rid="b17-ijmm-46-02-0463" ref-type="bibr">17</xref>) has drastically reduced the time required. Strongly accelerated development and implementation (relative to standard vaccine development times) is the goal; bypassing some critical steps in the vaccine development process is troubling. While much of the vaccine development and testing effort focuses on efficacy, it is difficult to see how true long-term safety can be validated within these limited time scales.</p><p>Numerous mid- and longer-term potential adverse effects from vaccines have been identified. These include: i) Antibody-dependent enhancement (where enhanced virus entry and replication in a number of cell types is enabled by antibodies) (<xref rid="b18-ijmm-46-02-0463" ref-type="bibr">18</xref>,<xref rid="b19-ijmm-46-02-0463" ref-type="bibr">19</xref>); ii) vaccine-associated virus interference (where vaccinated individuals may be at increased risk for other respiratory viruses because they do not receive the non-specific immunity associated with natural infection) (<xref rid="b20-ijmm-46-02-0463" ref-type="bibr">20</xref>-<xref rid="b21-ijmm-46-02-0463" ref-type="bibr">21</xref>); iii) vaccine-associated imprinting reduction (where vaccinations could also reduce the benefits of 'imprinting', a protection conferred upon children who experienced infection at an early age) (<xref rid="b22-ijmm-46-02-0463" ref-type="bibr">22</xref>,<xref rid="b23-ijmm-46-02-0463" ref-type="bibr">23</xref>); iv) Non-specific vaccine effects on immune system (where previous infections can alter an individual's susceptibility to unrelated diseases) (<xref rid="b24-ijmm-46-02-0463" ref-type="bibr">24</xref>,<xref rid="b25-ijmm-46-02-0463" ref-type="bibr">25</xref>); v) impact of infection route on immune system (where immune protection can be influenced by the route of exposure/delivery) (<xref rid="b26-ijmm-46-02-0463" ref-type="bibr">26</xref>,<xref rid="b27-ijmm-46-02-0463" ref-type="bibr">27</xref>); and vi) impact of combinations of toxic stimuli (where people are exposed over their lifetime to myriad toxic stimuli that may impact the influence of any vaccine) (<xref rid="b28-ijmm-46-02-0463" ref-type="bibr">28</xref>).</p><p>Many more specific potential vaccine adverse effects in the mid-term are presented in our upcoming COVID-19 mono-graph (<ext-link ext-link-type="uri" xlink:href="https://smartech.gatech.edu/handle/1853/62907">https://smartech.gatech.edu/handle/1853/62907</ext-link>).</p><p>The myriad of potential adverse impacts of vaccines cannot be identified in short-term tests characteristic of efficacy testing, but require long-term testing under real-life conditions (exposures to multiple toxic stimuli). Therefore, it is difficult to see how vaccines validated for short-, mid-, and long-term safety can be brought to market anytime soon.</p><p><italic>Strengthening immune system intrinsically</italic>. The fourth, and least emphasized, approach is strengthening the immune system intrinsically. This is accomplished using two parallel approaches: i) identifying those factors that contribute to weakening the immune system, then eliminating/reducing them as comprehensively, thoroughly, and rapidly as possible; ii) replacing the eliminated factors with immune-strengthening factors (<xref rid="b28-ijmm-46-02-0463" ref-type="bibr">28</xref>,<xref rid="b29-ijmm-46-02-0463" ref-type="bibr">29</xref>).</p><p><italic>Eliminating factors that weaken immune system</italic>. Our group has recently examined thousands of article Abstracts identifying factors that weaken the immune system. We have identified hundreds of factors (depending on how they are aggregated) that contribute to weakening the immune system (<xref rid="b29-ijmm-46-02-0463" ref-type="bibr">29</xref>). The complete study showing all the factors identified will be posted online by 20 June 2020 (<ext-link ext-link-type="uri" xlink:href="https://smartech.gatech.edu/handle/1853/62907">https://smartech.gatech.edu/handle/1853/62907</ext-link>).</p><p>Some of the factors in our study that have been shown repeatedly to weaken the immune system include:
<list list-type="roman-lower"><list-item><p>Lifestyle (e.g., smoking, excess alcohol, substance abuse, high-fat diet, protein-deficient diet, high-cholesterol diet, Western-style diets and chronic sleep restriction);</p></list-item><list-item><p>Iatrogenic (e.g., immunosuppressive drugs, gamma radiation treatments, nanomedicinal products, adjuvanted vaccines, acetaminophen, non-steroidal antiinflammatory drugs (NSAIDs), surgical stress, serotonin reuptake inhibitors, selected anasthetics, selected antibiotics and highly active antiretroviral therapy drugs);</p></list-item><list-item><p>Biotoxins/Biomaterials (e.g., aflatoxin, ochratoxin, T-2 toxin, anatoxin-A, mycotoxins, microcystin-LR, dietary toxic cyanobacteria, yessotoxin, scorpion venom; <italic>Streptomyces californicus; Pseudomonas aeruginosa</italic>; Rhinovirus and respiratory syncytial virus);</p></list-item><list-item><p>Occupational/Environmental (e.g., microplastics, endocrine-disrupting chemicals, heavy metals, pesticides/insecticides/herbicides, nanoparticles, perfluorooctanoic acid (PFOA), polychlorinated biphenyls (PCBs), polyaromatic hydrocarbons (PAHs), perfluorooctanesulfonate (PFOS), fine particulate matter, air pollution, acrylamide, aromatic halogenated disinfection byproducts, benzene, benzo(a)pyrene, crude oil, corexit, ultraviolet (UV) radiation, wireless radiation-cell phones/cell towers/WiFi and sodium fluoride);</p></list-item><list-item><p>PsychoSocial/SocioEconomic (e.g., depression, chronic stress, restraint stress, social isolation, stressful life events, and childhood adversity).</p></list-item></list></p><p>Eliminating/ameliorating these toxic exposures/behaviors will require a combination of individual motivations/efforts and government efforts, especially at the regulatory level.</p><p><italic>Adding factors that strengthen the immune system</italic>. A number of studies have identified factors (especially related to diet, nutrition, exercise, and sleep) that can strengthen the immune system. A recent article summarized the dietary component as follows: 'Evidence indicates that a diet that positively impacts immune function contains adequate amounts of protein, particularly including glutamine, arginine and branched-chain amino acids (BCAAs); high omega-3 versus lower saturated, trans fat, and omega-6 fatty acids, low refined sugars, high fiber content such as whole grains, and micronutrients including vitamin A, vitamin D, vitamin C, vitamin E, B vitamins, zinc, selenium and iron, as well as phytochemicals' (<xref rid="b29-ijmm-46-02-0463" ref-type="bibr">29</xref>,<xref rid="b30-ijmm-46-02-0463" ref-type="bibr">30</xref>). Table II in this reference provides many examples of foods rich in these desirable immune-strengthening factors.</p><p>Other favorable factors for enhancing immune system performance can be found in the following references (<xref rid="b31-ijmm-46-02-0463" ref-type="bibr">31</xref>-<xref rid="b43-ijmm-46-02-0463" ref-type="bibr">43</xref>).</p></sec><sec sec-type="other"><title>Summary</title><p>To summarize, first, there is no unanimity within the medical community for continuing the severe restrictions on activities of the vast majority of the total population that are mainly applicable to the most vulnerable, very small minority of the total population. Second, repurposed (mainly) antiviral treatments can only be expected to have very limited results in controlling SARS-CoV-2 viral load of the most severely impacted, based on trials conducted so far. Third, it is difficult to see how safe COVID-19 vaccines can be developed and fully tested on time scales of one or two years, as proposed presently.</p><p>Fourth, the only real protection against a future COVID-19 pandemic or any other viral pandemic is the one that was demonstrated to work in the SARS, MERS, COVID-19 and annual influenza pandemics: a healthy immune system capable of neutralizing incoming viruses as nature intended. We need an Operation Warp Speed (currently working to produce a vaccine in a record short time period in the USA) to identify and eliminate those factors that weaken the immune system as thoroughly, comprehensively, and rapidly as possible.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>Contributing factor data will be available on the SMARTech archive: <ext-link ext-link-type="uri" xlink:href="https://smartech.gatech.edu/handle/1853/62907">https://smartech.gatech.edu/handle/1853/62907</ext-link></p></sec></body><back><ref-list><title>References</title><ref id="b1-ijmm-46-02-0463"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><fpage>497</fpage><lpage>506</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><!--<pub-id pub-id-type="pmcid">7159299</pub-id>--><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b2-ijmm-46-02-0463"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</article-title><source>Sci China Life Sci</source><volume>63</volume><fpage>364</fpage><lpage>374</lpage><year>2020</year><pub-id pub-id-type="doi">10.1007/s11427-020-1643-8</pub-id><!--<pub-id pub-id-type="pmcid">7088566</pub-id>--><?supplied-pmid 32048163?><pub-id pub-id-type="pmid">32048163</pub-id></element-citation></ref><ref id="b3-ijmm-46-02-0463"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>P</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China</article-title><source>Clin Infect Dis</source><month>3</month><day>16</day><year>2020</year><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1093/cid/ciaa270</pub-id><!--<pub-id pub-id-type="pmcid">7184444</pub-id>--><?supplied-pmid 32173725?><pub-id pub-id-type="pmid">32173725</pub-id></element-citation></ref><ref id="b4-ijmm-46-02-0463"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>GQ</given-names></name><name><surname>Yang</surname><given-names>NB</given-names></name><name><surname>Ding</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>AHY</given-names></name><name><surname>Wang</surname><given-names>ZY</given-names></name><name><surname>Shen</surname><given-names>YF</given-names></name><name><surname>Shi</surname><given-names>CW</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series</article-title><source>QJM</source><month>3</month><day>17</day><year>2020</year><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1093/qjmed/hcaa089</pub-id></element-citation></ref><ref id="b5-ijmm-46-02-0463"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Shang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>DS</given-names></name></person-group><article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title><source>Clin Infect Dis</source><month>3</month><day>12</day><year>2020</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="b6-ijmm-46-02-0463"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Characteristics of COVID-19 infection in Beijing</article-title><source>J Infect</source><volume>80</volume><fpage>401</fpage><lpage>406</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.018</pub-id><!--<pub-id pub-id-type="pmcid">7102527</pub-id>--><?supplied-pmid 32112886?><pub-id pub-id-type="pmid">32112886</pub-id></element-citation></ref><ref id="b7-ijmm-46-02-0463"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors</article-title><source>Emerg Microbes Infect</source><volume>9</volume><fpage>1123</fpage><lpage>1130</lpage><year>2020</year><pub-id pub-id-type="doi">10.1080/22221751.2020.1770129</pub-id><?supplied-pmid 32475230?><pub-id pub-id-type="pmid">32475230</pub-id></element-citation></ref><ref id="b8-ijmm-46-02-0463"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name></person-group><article-title>Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients</article-title><source>Clin Chim Acta</source><volume>507</volume><fpage>94</fpage><lpage>97</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cca.2020.04.018</pub-id><!--<pub-id pub-id-type="pmcid">7166029</pub-id>--><?supplied-pmid 32315614?><pub-id pub-id-type="pmid">32315614</pub-id></element-citation></ref><ref id="b9-ijmm-46-02-0463"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medetalibeyo&#x0011f;lu</surname><given-names>A</given-names></name><name><surname>&#x0015e;enkal</surname><given-names>N</given-names></name><name><surname>&#x000c7;apar</surname><given-names>G</given-names></name><name><surname>K&#x000f6;se</surname><given-names>M</given-names></name><name><surname>T&#x000fc;kek</surname><given-names>T</given-names></name></person-group><article-title>Characteristics of the initial patients hospitalized for COVID-19: A single-center report</article-title><source>Turk J Med Sci</source><month>6</month><day>3</day><year>2020</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="b10-ijmm-46-02-0463"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>D</given-names></name><name><surname>Ouyang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical characteristics of elderly patients with COVID-19 in Hunan province, China: A multi-center, retrospective study</article-title><source>Gerontology</source><month>5</month><day>29</day><year>2020</year><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1159/000508734</pub-id></element-citation></ref><ref id="b11-ijmm-46-02-0463"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docea</surname><given-names>AO</given-names></name><name><surname>Tsatsakis</surname><given-names>A</given-names></name><name><surname>Albulescu</surname><given-names>D</given-names></name><name><surname>Cristea</surname><given-names>O</given-names></name><name><surname>Zlatian</surname><given-names>O</given-names></name><name><surname>Vinceti</surname><given-names>M</given-names></name><name><surname>Moschos</surname><given-names>SA</given-names></name><name><surname>Tsoukalas</surname><given-names>D</given-names></name><name><surname>Goumenou</surname><given-names>M</given-names></name><name><surname>Drakoulis</surname><given-names>N</given-names></name><etal/></person-group><article-title>A new threat from an old enemy: Re-emergence of coronavirus (Review)</article-title><source>Int J Mol Med</source><volume>45</volume><fpage>1631</fpage><lpage>1643</lpage><year>2020</year><!--<pub-id pub-id-type="pmcid">7169834</pub-id>--><?supplied-pmid 32236624?><pub-id pub-id-type="pmid">32236624</pub-id></element-citation></ref><ref id="b12-ijmm-46-02-0463"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrakis</surname><given-names>D</given-names></name><name><surname>Margin&#x00103;</surname><given-names>D</given-names></name><name><surname>Tsarouhas</surname><given-names>K</given-names></name><name><surname>Tekos</surname><given-names>F</given-names></name><name><surname>Stan</surname><given-names>M</given-names></name><name><surname>Nikitovic</surname><given-names>D</given-names></name><name><surname>Kouretas</surname><given-names>D</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Tsatsakis</surname><given-names>A</given-names></name></person-group><article-title>Obesity a risk factor for increased COVID-19 prevalence, severity and lethality (Review)</article-title><source>Mol Med Rep</source><volume>22</volume><fpage>9</fpage><lpage>19</lpage><year>2020</year><!--<pub-id pub-id-type="pmcid">7248467</pub-id>--><?supplied-pmid 32377709?><pub-id pub-id-type="pmid">32377709</pub-id></element-citation></ref><ref id="b13-ijmm-46-02-0463"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>SC</given-names></name><name><surname>Uyemura</surname><given-names>K</given-names></name><name><surname>Rafi</surname><given-names>A</given-names></name><name><surname>Akande</surname><given-names>O</given-names></name><name><surname>Makinodan</surname><given-names>T</given-names></name></person-group><article-title>Comorbidity is a better predictor of impaired immunity than chronological age in older adults</article-title><source>J Am Geriatr Soc</source><volume>53</volume><fpage>1565</fpage><lpage>1569</lpage><year>2005</year><pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53512.x</pub-id><?supplied-pmid 16137288?><pub-id pub-id-type="pmid">16137288</pub-id></element-citation></ref><ref id="b14-ijmm-46-02-0463"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>SC</given-names></name><name><surname>Uyemura</surname><given-names>K</given-names></name><name><surname>Fulop</surname><given-names>T</given-names></name><name><surname>Makinodan</surname><given-names>T</given-names></name></person-group><article-title>Host resistance and immune responses in advanced age</article-title><source>Clinics Geriatric Med</source><volume>23</volume><fpage>463</fpage><lpage>479</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.cger.2007.03.005</pub-id></element-citation></ref><ref id="b15-ijmm-46-02-0463"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitulescu</surname><given-names>GM</given-names></name><name><surname>Paunescu</surname><given-names>H</given-names></name><name><surname>Moschos</surname><given-names>SA</given-names></name><name><surname>Petrakis</surname><given-names>D</given-names></name><name><surname>Nitulescu</surname><given-names>G</given-names></name><name><surname>Ion</surname><given-names>GND</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Nikolouzakis</surname><given-names>TK</given-names></name><name><surname>Drakoulis</surname><given-names>N</given-names></name><name><surname>Tsatsakis</surname><given-names>A</given-names></name></person-group><article-title>Comprehensive analysis of drugs to treat SARS CoV 2 infection: Mechanistic insights into current COVID-19 therapies (Review)</article-title><source>Int J Mol Med</source><volume>46</volume><fpage>467</fpage><lpage>488</lpage><year>2020</year></element-citation></ref><ref id="b16-ijmm-46-02-0463"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stancioiu</surname><given-names>F</given-names></name><name><surname>Papadakis</surname><given-names>GZ</given-names></name><name><surname>Kteniadakis</surname><given-names>S</given-names></name><name><surname>Izotov</surname><given-names>BN</given-names></name><name><surname>Coleman</surname><given-names>MD</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Tsatsakis</surname><given-names>A</given-names></name></person-group><article-title>A dissection of SARS-CoV2 with clinical implications (Review)</article-title><source>Int J Mol Med</source><volume>46</volume><fpage>489</fpage><lpage>508</lpage><year>2020</year></element-citation></ref><ref id="b17-ijmm-46-02-0463"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calina</surname><given-names>D</given-names></name><name><surname>Docea</surname><given-names>AO</given-names></name><name><surname>Petrakis</surname><given-names>D</given-names></name><name><surname>Egorov</surname><given-names>AM</given-names></name><name><surname>Ishmukhametov</surname><given-names>AA</given-names></name><name><surname>Gabibov</surname><given-names>AG</given-names></name><name><surname>Shtilman</surname><given-names>MI</given-names></name><name><surname>Kostoff</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>F</given-names></name><name><surname>Vinceti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)</article-title><source>Int J Mol Med</source><volume>46</volume><fpage>3</fpage><lpage>16</lpage><year>2020</year><!--<pub-id pub-id-type="pmcid">7255458</pub-id>--></element-citation></ref><ref id="b18-ijmm-46-02-0463"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huisman</surname><given-names>W</given-names></name><name><surname>Martina</surname><given-names>BEE</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Gruters</surname><given-names>RA</given-names></name><name><surname>Osterhaus</surname><given-names>ADME</given-names></name></person-group><article-title>Vaccine-induced enhancement of viral infections</article-title><source>Vaccine</source><volume>27</volume><fpage>505</fpage><lpage>512</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.087</pub-id><pub-id pub-id-type="pmid">19022319</pub-id></element-citation></ref><ref id="b19-ijmm-46-02-0463"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Foo</surname><given-names>S-S</given-names></name><name><surname>Bruzzone</surname><given-names>R</given-names></name><name><surname>Dinh</surname><given-names>LV</given-names></name><name><surname>King</surname><given-names>NJC</given-names></name><name><surname>Mahalingam</surname><given-names>S</given-names></name></person-group><article-title>Fc receptors in antibody-dependent enhancement of viral infections</article-title><source>Immunol Rev</source><volume>268</volume><fpage>340</fpage><lpage>364</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/imr.12367</pub-id><!--<pub-id pub-id-type="pmcid">7165974</pub-id>--><?supplied-pmid 26497532?><pub-id pub-id-type="pmid">26497532</pub-id></element-citation></ref><ref id="b20-ijmm-46-02-0463"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>GG</given-names></name></person-group><article-title>Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season</article-title><source>Vaccine</source><volume>38</volume><fpage>350</fpage><lpage>354</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.10.005</pub-id><pub-id pub-id-type="pmid">31607599</pub-id></element-citation></ref><ref id="b21-ijmm-46-02-0463"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Fang</surname><given-names>VJ</given-names></name><name><surname>Nishiura</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Ng</surname><given-names>S</given-names></name><name><surname>Ip</surname><given-names>DK</given-names></name><name><surname>Chiu</surname><given-names>SS</given-names></name><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name></person-group><article-title>Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine</article-title><source>Clin Infect Dis</source><volume>54</volume><fpage>1778</fpage><lpage>1783</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/cid/cis307</pub-id><!--<pub-id pub-id-type="pmcid">3404712</pub-id>--><?supplied-pmid 22423139?><pub-id pub-id-type="pmid">22423139</pub-id></element-citation></ref><ref id="b22-ijmm-46-02-0463"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skowronski</surname><given-names>DM</given-names></name><name><surname>Sabaiduc</surname><given-names>S</given-names></name><name><surname>Leir</surname><given-names>S</given-names></name><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Murti</surname><given-names>M</given-names></name><name><surname>Dickinson</surname><given-names>JA</given-names></name><name><surname>Olsha</surname><given-names>R</given-names></name><name><surname>Gubbay</surname><given-names>JB</given-names></name><name><surname>Croxen</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)</article-title><source>Euro Surveill</source><volume>24</volume><fpage>1900585</fpage><year>2019</year><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2019.24.46.1900585</pub-id><!--<pub-id pub-id-type="pmcid">6864978</pub-id>--></element-citation></ref><ref id="b23-ijmm-46-02-0463"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelvin</surname><given-names>AA</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><article-title>Influenza imprinting in childhood and the influence on vaccine response later in life</article-title><source>Euro Surveill</source><volume>24</volume><fpage>1900720</fpage><year>2019</year><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2019.24.48.1900720</pub-id><!--<pub-id pub-id-type="pmcid">6891942</pub-id>--></element-citation></ref><ref id="b24-ijmm-46-02-0463"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><article-title>A small jab - a big effect: Nonspecific immunomodulation by vaccines</article-title><source>Trends Immunol</source><volume>34</volume><fpage>431</fpage><lpage>439</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.it.2013.04.004</pub-id><?supplied-pmid 23680130?><pub-id pub-id-type="pmid">23680130</pub-id></element-citation></ref><ref id="b25-ijmm-46-02-0463"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakebrandt</surname><given-names>N</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name></person-group><article-title>Infection history determines susceptibility to unrelated diseases</article-title><source>BioEssays</source><volume>41</volume><fpage>e1800191</fpage><year>2019</year><pub-id pub-id-type="doi">10.1002/bies.201800191</pub-id><?supplied-pmid 31132173?><pub-id pub-id-type="pmid">31132173</pub-id></element-citation></ref><ref id="b26-ijmm-46-02-0463"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demars</surname><given-names>A</given-names></name><name><surname>Lison</surname><given-names>A</given-names></name><name><surname>Machelart</surname><given-names>A</given-names></name><name><surname>Van Vyve</surname><given-names>M</given-names></name><name><surname>Potemberg</surname><given-names>G</given-names></name><name><surname>Vanderwinden</surname><given-names>JM</given-names></name><name><surname>De Bolle</surname><given-names>X</given-names></name><name><surname>Letesson</surname><given-names>JJ</given-names></name><name><surname>Muraille</surname><given-names>E</given-names></name></person-group><article-title>Route of infection strongly impacts the host-pathogen relationship</article-title><source>Front Immunol</source><volume>10</volume><fpage>1589</fpage><year>2019</year><pub-id pub-id-type="doi">10.3389/fimmu.2019.01589</pub-id><!--<pub-id pub-id-type="pmcid">6637429</pub-id>--><?supplied-pmid 31354728?><pub-id pub-id-type="pmid">31354728</pub-id></element-citation></ref><ref id="b27-ijmm-46-02-0463"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>DW</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Goodwin</surname><given-names>Z</given-names></name><name><surname>Hoffman</surname><given-names>C</given-names></name><name><surname>Clapp</surname><given-names>B</given-names></name></person-group><article-title>Alternative strategies for vaccination to brucellosis</article-title><source>Microbes Infect</source><volume>20</volume><fpage>599</fpage><lpage>605</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.micinf.2017.12.006</pub-id><!--<pub-id pub-id-type="pmcid">6019614</pub-id>--><pub-id pub-id-type="pmid">29287984</pub-id></element-citation></ref><ref id="b28-ijmm-46-02-0463"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostoff</surname><given-names>RN</given-names></name><name><surname>Goumenou</surname><given-names>M</given-names></name><name><surname>Tsatsakis</surname><given-names>A</given-names></name></person-group><article-title>The role of toxic stimuli combinations in determining safe exposure limits</article-title><source>Toxicol Rep</source><volume>5</volume><fpage>1169</fpage><lpage>1172</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.toxrep.2018.10.010</pub-id><pub-id pub-id-type="pmid">30627517</pub-id></element-citation></ref><ref id="b29-ijmm-46-02-0463"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsatsakis</surname><given-names>A</given-names></name><name><surname>Petrakis</surname><given-names>D</given-names></name><name><surname>Nikolouzakis</surname><given-names>TK</given-names></name><name><surname>Docea</surname><given-names>AO</given-names></name><name><surname>Calina</surname><given-names>D</given-names></name><name><surname>Vinceti</surname><given-names>M</given-names></name><name><surname>Goumenou</surname><given-names>M</given-names></name><name><surname>Kostoff</surname><given-names>RN</given-names></name><name><surname>Mamoulakis</surname><given-names>C</given-names></name><name><surname>Aschner</surname><given-names>M</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>AF</given-names></name></person-group><article-title>COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence</article-title><source>Food Chem Toxicol</source><volume>141</volume><fpage>111418</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.fct.2020.111418</pub-id><!--<pub-id pub-id-type="pmcid">7211730</pub-id>--><?supplied-pmid 32437891?><pub-id pub-id-type="pmid">32437891</pub-id></element-citation></ref><ref id="b30-ijmm-46-02-0463"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iddir</surname><given-names>M</given-names></name><name><surname>Brito</surname><given-names>A</given-names></name><name><surname>Dingeo</surname><given-names>G</given-names></name><name><surname>Fernandez Del Campo</surname><given-names>SS</given-names></name><name><surname>Samouda</surname><given-names>H</given-names></name><name><surname>La Frano</surname><given-names>MR</given-names></name><name><surname>Bohn</surname><given-names>T</given-names></name></person-group><article-title>Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: Considerations during the COVID-19 Crisis</article-title><source>Nutrients</source><volume>12</volume><fpage>12</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/nu12061562</pub-id></element-citation></ref><ref id="b31-ijmm-46-02-0463"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilashi</surname><given-names>M</given-names></name><name><surname>Samad</surname><given-names>S</given-names></name><name><surname>Yusuf</surname><given-names>SYM</given-names></name><name><surname>Akbari</surname><given-names>E</given-names></name></person-group><article-title>Can complementary and alternative medicines be beneficial in the treatment of COVID-19 through improving immune system function?</article-title><source>J Infect Public Health</source><volume>13</volume><fpage>893</fpage><lpage>896</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jiph.2020.05.009</pub-id><!--<pub-id pub-id-type="pmcid">7237937</pub-id>--><?supplied-pmid 32451258?><pub-id pub-id-type="pmid">32451258</pub-id></element-citation></ref><ref id="b32-ijmm-46-02-0463"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham-Rundles</surname><given-names>S</given-names></name><name><surname>McNeeley</surname><given-names>DF</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of nutrient modulation of the immune response</article-title><source>J Allergy Clin Immunol</source><volume>115</volume><fpage>1119</fpage><lpage>1128</lpage><comment>quiz 1129</comment><year>2005</year><pub-id pub-id-type="doi">10.1016/j.jaci.2005.04.036</pub-id><?supplied-pmid 15940121?><pub-id pub-id-type="pmid">15940121</pub-id></element-citation></ref><ref id="b33-ijmm-46-02-0463"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mainardi</surname><given-names>T</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Bielory</surname><given-names>L</given-names></name></person-group><article-title>Complementary and alternative medicine: Herbs, phytochemicals and vitamins and their immunologic effects</article-title><source>J Allergy Clin Immunol</source><volume>123</volume><fpage>283</fpage><lpage>294</lpage><comment>quiz 295-296</comment><year>2009</year><pub-id pub-id-type="doi">10.1016/j.jaci.2008.12.023</pub-id><?supplied-pmid 19203652?><pub-id pub-id-type="pmid">19203652</pub-id></element-citation></ref><ref id="b34-ijmm-46-02-0463"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahns</surname><given-names>L</given-names></name><name><surname>Conrad</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>LK</given-names></name><name><surname>Whigham</surname><given-names>LD</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Claycombe-Larson</surname><given-names>KJ</given-names></name></person-group><article-title>A diet high in carotenoid-rich vegetables and fruits favorably impacts inflammation status by increasing plasma concentrations of IFN-&#x003b1;2 and decreasing MIP-1&#x003b2; and TNF-&#x003b1; in healthy individuals during a controlled feeding trial</article-title><source>Nutr Res</source><volume>52</volume><fpage>98</fpage><lpage>104</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.nutres.2018.02.005</pub-id><?supplied-pmid 29551222?><pub-id pub-id-type="pmid">29551222</pub-id></element-citation></ref><ref id="b35-ijmm-46-02-0463"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majde</surname><given-names>JA</given-names></name><name><surname>Krueger</surname><given-names>JM</given-names></name></person-group><article-title>Links between the innate immune system and sleep</article-title><source>J Allergy Clin Immunol</source><volume>116</volume><fpage>1188</fpage><lpage>1198</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.jaci.2005.08.005</pub-id><?supplied-pmid 16337444?><pub-id pub-id-type="pmid">16337444</pub-id></element-citation></ref><ref id="b36-ijmm-46-02-0463"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>RK</given-names></name></person-group><article-title>Nutrition, immunity and infection: From basic knowledge of dietary manipulation of immune responses to practical application of ameliorating suffering and improving survival</article-title><source>Proc Natl Acad Sci USA</source><volume>93</volume><fpage>14304</fpage><lpage>14307</lpage><year>1996</year><pub-id pub-id-type="doi">10.1073/pnas.93.25.14304</pub-id><!--<pub-id pub-id-type="pmcid">34479</pub-id>--><?supplied-pmid 8962043?><pub-id pub-id-type="pmid">8962043</pub-id></element-citation></ref><ref id="b37-ijmm-46-02-0463"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briguglio</surname><given-names>M</given-names></name><name><surname>Pregliasco</surname><given-names>FE</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Perazzo</surname><given-names>P</given-names></name><name><surname>Banfi</surname><given-names>G</given-names></name></person-group><article-title>The malnutritional status of the host as a virulence factor for new coronavirus SARS-CoV-2</article-title><source>Front Med (Lausanne)</source><volume>7</volume><fpage>146</fpage><year>2020</year><pub-id pub-id-type="pmid">32391367</pub-id></element-citation></ref><ref id="b38-ijmm-46-02-0463"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>A</given-names></name><name><surname>Nova</surname><given-names>E</given-names></name><name><surname>Montero</surname><given-names>A</given-names></name></person-group><article-title>Changes in the immune system are conditioned by nutrition</article-title><source>Eur J Clin Nutr</source><volume>57</volume><issue>Suppl 1</issue><fpage>S66</fpage><lpage>S69</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/sj.ejcn.1601819</pub-id><?supplied-pmid 12947457?><pub-id pub-id-type="pmid">12947457</pub-id></element-citation></ref><ref id="b39-ijmm-46-02-0463"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley-Evans</surname><given-names>SC</given-names></name><name><surname>Carrington</surname><given-names>LJ</given-names></name></person-group><article-title>Diet and the developing immune system</article-title><source>Lupus</source><volume>15</volume><fpage>746</fpage><lpage>752</lpage><year>2006</year><pub-id pub-id-type="doi">10.1177/0961203306070001</pub-id><?supplied-pmid 17153845?><pub-id pub-id-type="pmid">17153845</pub-id></element-citation></ref><ref id="b40-ijmm-46-02-0463"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>B</given-names></name></person-group><article-title>The impact of dietary fiber and probiotics in infectious diseases</article-title><source>Microb Pathog</source><volume>140</volume><fpage>103931</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103931</pub-id><pub-id pub-id-type="pmid">31846741</pub-id></element-citation></ref><ref id="b41-ijmm-46-02-0463"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>F</given-names></name><name><surname>Nadeem</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>RS</given-names></name><name><surname>Nadeem</surname><given-names>MT</given-names></name><name><surname>Arshad</surname><given-names>MS</given-names></name><name><surname>Ullah</surname><given-names>A</given-names></name></person-group><article-title>Studying the impact of nutritional immunology underlying the modulation of immune responses by nutritional compounds - a review</article-title><source>Food Agric Immunol</source><volume>27</volume><fpage>205</fpage><lpage>229</lpage><year>2016</year><pub-id pub-id-type="doi">10.1080/09540105.2015.1079600</pub-id></element-citation></ref><ref id="b42-ijmm-46-02-0463"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davison</surname><given-names>G</given-names></name><name><surname>Kehaya</surname><given-names>C</given-names></name><name><surname>Wyn Jones</surname><given-names>A</given-names></name></person-group><article-title>Nutritional and physical activity interventions to improve immunity</article-title><source>Am J Lifestyle Med</source><volume>10</volume><fpage>152</fpage><lpage>169</lpage><year>2014</year><pub-id pub-id-type="doi">10.1177/1559827614557773</pub-id><!--<pub-id pub-id-type="pmcid">6124954</pub-id>--><?supplied-pmid 30202268?><pub-id pub-id-type="pmid">30202268</pub-id></element-citation></ref><ref id="b43-ijmm-46-02-0463"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skalny</surname><given-names>AV</given-names></name><name><surname>Rink</surname><given-names>L</given-names></name><name><surname>Ajsuvakova</surname><given-names>OP</given-names></name><name><surname>Aschner</surname><given-names>M</given-names></name><name><surname>Gritsenko</surname><given-names>VA</given-names></name><name><surname>Alekseenko</surname><given-names>SI</given-names></name><name><surname>Svistunov</surname><given-names>AA</given-names></name><name><surname>Petrakis</surname><given-names>D</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Aaseth</surname><given-names>J</given-names></name><etal/></person-group><article-title>Zinc and respiratory tract infections: Perspectives for COVID-19 (Review)</article-title><source>Int J Mol Med</source><volume>46</volume><fpage>17</fpage><lpage>26</lpage><year>2020</year><!--<pub-id pub-id-type="pmcid">7255455</pub-id>--></element-citation></ref></ref-list></back></article>